Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Trends Cancer. 2023 Apr;9(4):270-292. doi: 10.1016/j.trecan.2022.12.008. Epub 2023 Jan 19.
Despite advances in understanding tumor biology, malignant gliomas remain incurable. While immunotherapy has improved outcomes in other cancer types, comparable efficacy has not yet been demonstrated for primary cancers of the central nervous system (CNS). T cell exhaustion, defined as a progressive decrease in effector function, sustained expression of inhibitory receptors, metabolic dysfunction, and distinct epigenetic and transcriptional alterations, contributes to the failure of immunotherapy in the CNS. Herein, we describe recent advances in understanding the drivers of T cell exhaustion in the glioma microenvironment. We discuss the extrinsic and intrinsic factors that contribute to exhaustion and highlight potential avenues for reversing this phenotype. Our ability to directly target specific immunosuppressive drivers in brain cancers would be a major advance in immunotherapy.
尽管在肿瘤生物学方面取得了进展,但恶性脑胶质瘤仍然无法治愈。虽然免疫疗法已经改善了其他癌症类型的预后,但尚未在中枢神经系统(CNS)的原发性癌症中显示出可比的疗效。T 细胞耗竭被定义为效应功能逐渐下降、持续表达抑制性受体、代谢功能障碍以及独特的表观遗传和转录改变,这导致了 CNS 中免疫疗法的失败。在此,我们描述了在了解胶质瘤微环境中 T 细胞耗竭的驱动因素方面的最新进展。我们讨论了导致耗竭的外在和内在因素,并强调了逆转这种表型的潜在途径。我们能够直接针对脑癌中的特定免疫抑制性驱动因素,这将是免疫疗法的重大进展。